when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Monoclonal Antibody · news · pharmadog

← back to Monoclonal Antibody

News · Monoclonal Antibody

333 stories

Jul 6, 26STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and morestat

Jul 6, 26The race for an Ebola therapy beginsstat

Jul 6, 26Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platformendpoints

Jul 1, 26Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M dealbiopharma dive

Jul 1, 26STAT+: More signs that GLP-1s may help with peripheral artery diseasestat

Jun 30, 26AbbVie and Genmab's latest win brings Epkinly closer to label expansionendpoints

Jun 30, 26These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.biopharma dive

Jun 29, 2610 clinical trials to watch in the second half of 2026biopharma dive

Jun 26, 26On second try, Acadia drug gets nod from European regulatorsbiopharma dive

Jun 17, 26Jazz turns to AbCellera for T cell engagers in up to $4.1B partnershipendpoints

Jun 17, 26A new Westlake-backed biotech takes aim at migrainesbiopharma dive

Jun 16, 26The U.S. infant mortality rate fell to an all-time low, though it still trails other similar nationsstat

Jun 15, 26J&J multiple myeloma drug gains edge in earlier stage diseasebiopharma dive

Jun 15, 26Celiac disease is entering a new era of therapeutic innovationbiopharma dive

Jun 11, 26Nonprofit buys experimental cancer drug to maintain patient accessstat

Jun 10, 26Ethyreal starts up with $101M and takes aim at a pair of immune diseasesbiopharma dive

Jun 10, 26OB-GYN association, deviating from CDC guidance, issues its own vaccine recommendationsstat

Jun 10, 26Sanofi to mull riliprubart’s future after stopping late-stage nerve disease studyendpoints

Jun 9, 26Merck, Gilead report mixed outcomes in key lung cancer, HIV studiesbiopharma dive

Jun 9, 26Gilead and Merck’s latest trial success and flopstat

Jun 9, 26Opinion: Ending animal testing could set back xenotransplantation just as the field is poised for a breakthroughstat

Jun 8, 26J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1Bbiopharma dive

Jun 8, 26J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS fieldendpoints

Jun 8, 26STAT+: Novo underwhelmed by drug it once fought Pfizer forstat

Jun 5, 26Study data convince Lundbeck to push new migraine drug forwardbiopharma dive

Jun 5, 26Texas AG investigating energy drinksstat

Jun 5, 26Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?biopharma dive

Jun 4, 26HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapystat

Jun 4, 26Otsuka touts new IgAN evidence as it seeks full approval for Voyxactendpoints

Jun 4, 26An ADC specialist sinks on safety concerns for blood cancer drugbiopharma dive

← prevpage 7 of 12next →